Can cabozantinib be used for abdominal metastasis of lung cancer?

Cabozantinib is a multi-target tyrosine kinase inhibitor commonly used to treat many types of cancer. Although cabozantinib has shown certain efficacy in the treatment of some types of cancer, its treatment of abdominal metastasis of lung cancer has not been extensively studied and confirmed. Abdominal metastasis of lung cancer means that cancer cells have spread to the abdominal area beyond the primary tumor of the lung cancer, which increases the complexity and difficulty of treatment. At present, the treatment for abdominal metastasis of lung cancer usually includes the comprehensive application of multiple methods such as chemotherapy, radiotherapy, surgery, and targeted therapy. Nonetheless, cabozantinib, as a targeted therapy, may have a certain inhibitory effect on abdominal metastases in some patients with lung cancer. However, its efficacy and safety in this specific condition still require further clinical research and trials to verify. Therefore, when deciding on a treatment plan, patients should consult a professional doctor to jointly develop an individualized treatment plan suitable for their condition.